Cargando…
Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728448/ https://www.ncbi.nlm.nih.gov/pubmed/26703733 http://dx.doi.org/10.3390/cancers8010001 |
_version_ | 1782412112043180032 |
---|---|
author | Yaogawa, Shin Ogawa, Yasuhiro Morita-Tokuhiro, Shiho Tsuzuki, Akira Akima, Ryo Itoh, Kenji Morio, Kazuo Yasunami, Hiroaki Onogawa, Masahide Kariya, Shinji Nogami, Munenobu Nishioka, Akihito Miyamura, Mitsuhiko |
author_facet | Yaogawa, Shin Ogawa, Yasuhiro Morita-Tokuhiro, Shiho Tsuzuki, Akira Akima, Ryo Itoh, Kenji Morio, Kazuo Yasunami, Hiroaki Onogawa, Masahide Kariya, Shinji Nogami, Munenobu Nishioka, Akihito Miyamura, Mitsuhiko |
author_sort | Yaogawa, Shin |
collection | PubMed |
description | Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy. |
format | Online Article Text |
id | pubmed-4728448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-47284482016-02-08 Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging Yaogawa, Shin Ogawa, Yasuhiro Morita-Tokuhiro, Shiho Tsuzuki, Akira Akima, Ryo Itoh, Kenji Morio, Kazuo Yasunami, Hiroaki Onogawa, Masahide Kariya, Shinji Nogami, Munenobu Nishioka, Akihito Miyamura, Mitsuhiko Cancers (Basel) Article Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy. MDPI 2015-12-22 /pmc/articles/PMC4728448/ /pubmed/26703733 http://dx.doi.org/10.3390/cancers8010001 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yaogawa, Shin Ogawa, Yasuhiro Morita-Tokuhiro, Shiho Tsuzuki, Akira Akima, Ryo Itoh, Kenji Morio, Kazuo Yasunami, Hiroaki Onogawa, Masahide Kariya, Shinji Nogami, Munenobu Nishioka, Akihito Miyamura, Mitsuhiko Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging |
title | Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging |
title_full | Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging |
title_fullStr | Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging |
title_full_unstemmed | Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging |
title_short | Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging |
title_sort | serial assessment of therapeutic response to a new radiosensitization treatment, kochi oxydol-radiation therapy for unresectable carcinomas, type ii (kortuc ii), in patients with stage i/ii breast cancer using breast contrast-enhanced magnetic resonance imaging |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728448/ https://www.ncbi.nlm.nih.gov/pubmed/26703733 http://dx.doi.org/10.3390/cancers8010001 |
work_keys_str_mv | AT yaogawashin serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT ogawayasuhiro serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT moritatokuhiroshiho serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT tsuzukiakira serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT akimaryo serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT itohkenji serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT moriokazuo serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT yasunamihiroaki serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT onogawamasahide serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT kariyashinji serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT nogamimunenobu serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT nishiokaakihito serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging AT miyamuramitsuhiko serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging |